The Lancet JULY 06, 2002

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Heart Protection Study Collaborative Group

Bottom Line

The Heart Protection Study (HPS) demonstrated that daily administration of 40 mg simvastatin significantly reduced all-cause mortality and major vascular events in a broad, high-risk population, irrespective of baseline cholesterol levels.

Key Findings

1. All-cause mortality was significantly reduced by 12% (12.9% in the simvastatin group vs. 14.7% in the placebo group; p=0.0003), primarily driven by a 17-18% reduction in vascular deaths.

2. Major vascular events (non-fatal myocardial infarction, coronary death, stroke, or revascularization) were reduced by approximately 24% (19.9% vs. 25.4%; p<0.0001).

3. The risk of stroke was reduced by 27% (4.4% vs. 6.0%; p<0.00001), with benefit observed consistently across various high-risk subgroups, including those with low baseline cholesterol, women, the elderly, and patients with diabetes.

4. No evidence of increased risk for cancer, non-vascular mortality, or specific non-cardiac adverse events was observed, confirming the long-term safety of the regimen.

5. Antioxidant vitamin supplementation (vitamins E, C, and beta-carotene) provided no significant benefit in reducing major vascular events or mortality.

Study Design

Design

RCT

Double-Blind

Sample

20,536

Patients

Duration

5 yr

Median

Setting

Multicenter, UK

Population Men and women aged 40-80 years at high risk of coronary disease, occlusive arterial disease, or diabetes, with total cholesterol ≥3.5 mmol/L.

Intervention 40 mg simvastatin daily

Comparator Matching placebo

Outcome All-cause mortality and major vascular events (non-fatal myocardial infarction, coronary death, stroke, or revascularization)

Study Limitations

• The intention-to-treat analysis was influenced by significant non-compliance, with approximately 17% of the placebo group initiating non-study statin therapy, potentially diluting the observed treatment effect.

• The trial utilized a 2x2 factorial design to test both simvastatin and antioxidants; while the primary analysis focused on the simvastatin comparison, the complexity of managing two interventions may have had minor implications on trial execution.

• The study results are applicable to high-risk patients similar to those enrolled; generalizability to lower-risk populations or different age groups outside the 40-80 range is limited.

Clinical Significance

The HPS shifted clinical practice from a lipid-centric approach to a risk-based approach, establishing statin therapy as a foundational treatment for a broad spectrum of high-risk patients, even those with average or low baseline LDL cholesterol, effectively demonstrating that the absolute benefit is proportional to the patient's underlying vascular risk.

Historical Context

At the turn of the millennium, while earlier trials (like 4S and CARE) had confirmed statin benefits in specific populations with known coronary disease or high cholesterol, the Heart Protection Study provided definitive, large-scale evidence that expanded the indication for statins to a wider, high-risk population, including those previously thought to have insufficient lipid profiles to merit treatment.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

The Heart Protection Study (HPS) showed that simvastatin reduced vascular events even in patients with 'normal' or 'low' baseline LDL cholesterol. What does this suggest about the relationship between LDL levels and atherosclerosis progression?

Key Response

It suggests that there is no 'floor' for LDL benefit in high-risk patients. The findings support the 'lower is better' hypothesis, implying that even if a patient's cholesterol is within the traditionally defined 'normal' range, lowering it further with a statin provides significant cardioprotective benefits through both LDL reduction and potential pleiotropic effects like plaque stabilization.

Resident

A 65-year-old patient with type 2 diabetes but no history of myocardial infarction has an LDL of 110 mg/dL. Based on the HPS findings, what is the clinical justification for starting a statin?

Key Response

HPS was landmark for including a large subgroup of diabetic patients (nearly 6,000) and demonstrating that their risk reduction was proportional to that of patients with existing coronary heart disease. The study justified treating patients based on their overall cardiovascular risk profile (e.g., presence of diabetes) rather than treating only to a specific LDL threshold.

Fellow

HPS investigated the use of simvastatin in patients with peripheral artery disease (PAD) and cerebrovascular disease. How did the results for these specific subgroups influence our current approach to 'polyvascular' disease management?

Key Response

Prior to HPS, the evidence for statins in non-cardiac vascular disease was less robust. HPS showed that patients with PAD and prior stroke/TIA derived similar relative risk reductions in major vascular events as those with CHD. This shifted the subspecialty focus toward aggressive lipid management in all patients with any form of atherosclerotic occlusive disease, regardless of the primary vascular bed affected.

Attending

HPS used a fixed dose of 40mg simvastatin rather than a 'treat-to-target' protocol. How does this study design inform the debate between 'fire-and-forget' high-intensity statin therapy versus the 'treat-to-target' approach advocated by earlier guidelines?

Key Response

HPS provided strong evidence for a fixed-dose strategy, demonstrating that a standard dose of a potent-at-the-time statin produces significant mortality benefits across a heterogeneous high-risk population. This helped shift the paradigm from chasing numerical targets to ensuring that all high-risk patients receive at least a moderate-to-high intensity statin, a principle reflected in later ACC/AHA guideline iterations.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The HPS utilized a factorial design to test both simvastatin and antioxidant vitamins (Vitamin E, C, and beta-carotene). What are the statistical advantages and potential risks of using a 2x2 factorial design in a large-scale pragmatic trial of this nature?

Key Response

The advantage is efficiency, allowing researchers to test two independent hypotheses (statin efficacy and vitamin efficacy) within the same patient population at a lower cost than two separate trials. The primary risk is the assumption of 'no interaction' between the two interventions; if the vitamins had altered the metabolism or efficacy of simvastatin, the primary endpoint results for both arms could have been confounded.

Journal Editor

HPS employed an initial 6-week 'run-in' period where all participants took simvastatin to assess compliance and tolerance before randomization. How should a peer reviewer evaluate the impact of this run-in period on the trial's external validity (generalizability)?

Key Response

A run-in period enhances internal validity by ensuring the randomized cohort is compliant and tolerates the drug, which maximizes the power to see a treatment effect. However, it threatens external validity because it excludes patients who might experience early side effects or struggle with adherence in the real world, potentially leading to an overestimation of the treatment's 'effectiveness' compared to its 'efficacy' in a controlled setting.

Guideline Committee

At the time of HPS, guidelines often focused on LDL thresholds (e.g., LDL > 130 mg/dL). How did the HPS results necessitate a revision of the NCEP ATP III guidelines, and how is its legacy reflected in the current 2018/2019 AHA/ACC Multisociety guidelines?

Key Response

HPS was a primary driver for the 2004 NCEP ATP III update, which lowered treatment thresholds for high-risk patients. In current 2018/2019 guidelines, HPS's influence is seen in the 'Value of Statins' recommendations where 'High-Risk' groups (like those with DM or age 40-75 with specific risk factors) are recommended for statin therapy regardless of their baseline LDL, moving the focus from the 'number' to the 'patient risk profile'.

Clinical Landscape

Noteworthy Related Trials

1994

4S Study

n = 4,444 · Lancet

Tested

Simvastatin

Population

Patients with angina or previous myocardial infarction and hypercholesterolaemia

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Simvastatin treatment reduced total mortality by 30% and major coronary events by 34%.

1996

CARE Trial

n = 4,159 · NEJM

Tested

Pravastatin 40mg

Population

Patients with previous myocardial infarction and average cholesterol levels

Comparator

Placebo

Endpoint

Major coronary events

Key result: Pravastatin therapy significantly reduced the risk of recurrent coronary events and the need for revascularization procedures.

2003

ASCOT-LLA

n = 10,305 · Lancet

Tested

Atorvastatin 10mg

Population

Hypertensive patients with average total cholesterol levels

Comparator

Placebo

Endpoint

Non-fatal myocardial infarction and fatal coronary heart disease

Key result: Atorvastatin reduced the risk of coronary heart disease events and stroke in hypertensive patients with normal cholesterol.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis